Literature DB >> 21819696

Hemodynamic and histologic characterization of a swine (Sus scrofa domestica) model of chronic pulmonary arterial hypertension.

Abraham Rothman1, Robert G Wiencek, Stephanie Davidson, William N Evans, Humberto Restrepo, Valeri Sarukhanov, Amanda Rivera-Begeman, David Mann.   

Abstract

The purpose of this work was to develop and characterize an aortopulmonary shunt model of chronic pulmonary hypertension in swine and provide sequential hemodynamic, angiographic, and histologic data by using an experimental endoarterial biopsy catheter. Nine Yucatan female microswine (Sus scrofa domestica) underwent surgical anastomosis of the left pulmonary artery to the descending aorta. Sequential hemodynamic, angiographic, and pulmonary vascular samples were obtained. Six pigs (mean weight, 22.4±5.3 kg; mean age, 7.3±2.7 mo at surgery) survived long-term (6 mo) and consistently developed marked pulmonary arterial hypertension. Angiography showed characteristic central pulmonary arterial enlargement and peripheral tortuosity and pruning. The biopsy catheter was safe and effective in obtaining pulmonary endoarterial samples for histologic studies, which showed neointimal and medial changes. Autopsy confirmed severe pulmonary vascular changes, including concentric obstructive neointimal and plexiform-like lesions. This swine model showed hemodynamic, angiographic, and histologic characteristics of chronic pulmonary arterial hypertension that mimicked the arterial pulmonary hypertension of systemic-to-pulmonary arterial shunts in humans. Experimental data obtained using this and other models and application of an in vivo endoarterial biopsy technique may aid in understanding mechanisms and developing therapies for experimental and human pulmonary arterial hypertension. Copyright 2011 by the American Association for Laboratory Animal Science

Entities:  

Mesh:

Year:  2011        PMID: 21819696      PMCID: PMC3123759     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  51 in total

1.  Systemic lobar shunting induces advanced pulmonary vasculopathy.

Authors:  M Bousamra; R Rossi; E Jacobs; M Parviz; C Busch; L D Nelin; S Haworth; C A Dawson
Journal:  J Thorac Cardiovasc Surg       Date:  2000-07       Impact factor: 5.209

2.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Effect of a surgical aortocaval fistula on monocrotaline-induced pulmonary hypertension.

Authors:  Toshihiko Nishimura; John L Faul; Gerald J Berry; Peter N Kao; Ronald G Pearl
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

4.  Vascular remodeling in experimentally induced subacute canine pulmonary hypertension.

Authors:  R Gust; D P Schuster
Journal:  Exp Lung Res       Date:  2001 Jan - Feb       Impact factor: 2.459

5.  Effects of long-term bosentan in children with pulmonary arterial hypertension.

Authors:  Erika Berman Rosenzweig; D Dunbar Ivy; Allison Widlitz; Aimee Doran; Lori R Claussen; Delphine Yung; Steven H Abman; Adele Morganti; Ngoc Nguyen; Robyn J Barst
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

6.  Decreased synthesis and vasodilation to nitric oxide in piglets with hypoxia-induced pulmonary hypertension.

Authors:  J W Berkenbosch; J Baribeau; T Perreault
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-02       Impact factor: 5.464

7.  Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.

Authors:  H Kim; G L Yung; J J Marsh; R G Konopka; C A Pedersen; P G Chiles; T A Morris; R N Channick
Journal:  Eur Respir J       Date:  2000-04       Impact factor: 16.671

8.  A model of embolic chronic pulmonary hypertension in the dog.

Authors:  I Shelub; A van Grondelle; R McCullough; S Hofmeister; J T Reeves
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-03

9.  An experimental animal model of postobstructive pulmonary hypertension.

Authors:  Philipp Jungebluth; Helmut Ostertag; Paolo Macchiarini
Journal:  J Surg Res       Date:  2007-12-26       Impact factor: 2.192

10.  Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.

Authors:  James West; Karen Fagan; Wolfgang Steudel; Brian Fouty; Kirk Lane; Julie Harral; Marloes Hoedt-Miller; Yuji Tada; John Ozimek; Rubin Tuder; David M Rodman
Journal:  Circ Res       Date:  2004-03-18       Impact factor: 17.367

View more
  4 in total

1.  Assessment of microRNA and gene dysregulation in pulmonary hypertension by endoarterial biopsy.

Authors:  Abraham Rothman; Humberto Restrepo; Valeri Sarukhanov; William N Evans; Robert G Wiencek; Roy Williams; Nicole Hamburger; Kylie Anderson; Jasmine Balsara; David Mann
Journal:  Pulm Circ       Date:  2017-05-12       Impact factor: 3.017

2.  Challenges in the development of chronic pulmonary hypertension models in large animals.

Authors:  Abraham Rothman; Robert G Wiencek; Stephanie Davidson; William N Evans; Humberto Restrepo; Valeri Sarukhanov; David Mann
Journal:  Pulm Circ       Date:  2017-02-01       Impact factor: 3.017

3.  Vascular histomolecular analysis by sequential endoarterial biopsy in a shunt model of pulmonary hypertension.

Authors:  Abraham Rothman; Stephanie Davidson; Robert G Wiencek; William N Evans; Humberto Restrepo; Valeri Sarukhanov; Erkki Ruoslahti; Roy Williams; David Mann
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

4.  Quantification of tortuosity and fractal dimension of the lung vessels in pulmonary hypertension patients.

Authors:  Michael Helmberger; Michael Pienn; Martin Urschler; Peter Kullnig; Rudolf Stollberger; Gabor Kovacs; Andrea Olschewski; Horst Olschewski; Zoltán Bálint
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.